The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure

Gianluigi Savarese, Peter Vasko, Åsa Jonsson, Magnus Edner, Ulf Dahlström, Lars H Lund, Gianluigi Savarese, Peter Vasko, Åsa Jonsson, Magnus Edner, Ulf Dahlström, Lars H Lund

Abstract

Heart failure (HF) represents a global pandemic. Although in HF with reduced ejection fraction (HFrEF) randomized controlled trials have provided effective treatments, prognosis still remains poor, with signals of undertreatment. HF with mid-range EF (HFmrEF) has no evidence-based therapy, and its characterization is ongoing. Trials in HF with preserved EF (HFpEF) have failed to provide any effective treatment, but there are several concerns about their design. Thus, current challenges in the HF field are: 1) optimizing the use of existing treatments in HFrEF; 2) developing and proving efficacy of new treatments, and of new use of existing treatments in HFpEF and HFmrEF. Here we describe how registry-based research can improve knowledge addressing the unmet needs in HF, and in particular we focus on the contribution of the Swedish Heart Failure Registry to this field.

Keywords: Heart failure; RiksSvikt; SwedeHF; registry.

References

    1. Ambrosy AP, Gheorghiade M, Chioncel O, Mentz RJ, Butler J. Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes. Curr Heart Fail Rep. 2014;11:416–27.
    1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11.
    1. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail. 2008;1:91–7.
    1. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, et al. . Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002;87:235–41.
    1. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. . A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19:1624–34.
    1. Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH. Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. Eur J Heart Fail. 2016;18:503–11.
    1. Lund LH. Heart Failure With "Mid-Range" Ejection Fraction-New Opportunities. J Card Fail. 2016;22:769–71.
    1. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. . Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018. Feb 12; doi: 10.1002/ejhf.1149. [Epub ahead of print]
    1. Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, et al. . Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016;9:e002744.
    1. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. . Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455–62.
    1. Lund LH, Oldgren J, James S. Registry-based pragmatic trials in heart failure: current experience and future directions. Curr Heart Fail Rep. 2017;14:59–70.
    1. Jonsson A, Edner M, Alehagen U, Dahlstrom U. Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail. 2010;12:25–31.
    1. Lund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson Å, Jernberg T, et al. . Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study. Eur J Heart Fail. 2017;19:1107–16.
    1. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. . External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
    1. Ingelsson E, Arnlov J, Sundstrom J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7:787–91.
    1. Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, et al. . Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018. Apr 18; doi: 10.1002/ejhf.1199. [Epub ahead of print]
    1. Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlström U, et al. . Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018. Mar 26; doi: 10.1002/ejhf.1182. [Epub ahead of print]
    1. Savarese G, Sartipy U, Friberg L, Dahlstrom U, Lund LH. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. Heart. 2018;104:1093–100.
    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37:2893–962.
    1. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. . Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail. 2017;10 pii: e003875.
    1. Makubi A, Hage C, Sartipy U, Lwakatare J, Janabi M, Kisenge P, et al. . Heart failure in Tanzania and Sweden: comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF). Int J Cardiol. 2016;220:750–8.
    1. Gijsberts CM, Benson L, Dahlström U, Sim D, Yeo DP, Ong HY, et al. . Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. Heart. 2016;102:1464–71.
    1. Ahmad T, Lund LH, Rao P, Ghosh R, Warier P, Vaccaro B, et al. . Machine learning methods improve prognostication, identify clinically distinct phenotypes, and detect heterogeneity in response to therapy in a large cohort of heart failure patients. J Am Heart Assoc. 2018;7 pii: e008081.
    1. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. . Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.
    1. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308:2108–17.
    1. Lund LH, Benson L, Dahlstrom U, Edner M, Friberg L. Association between use of beta-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014;312:2008–18.
    1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.
    1. Edner M, Benson L, Dahlstrom U, Lund LH. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J. 2015;36:2318–26.
    1. Savarese G, Orsini N, Hage C, Vedin O, Cosentino F, Rosano GMC, et al. . Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF, HFmrEF, and HFrEF. JACC Heart Fail. 2018;6:246–56.
    1. Savarese G, Orsini N, Hage C, Dahlström U, Vedin O, Rosano GMC, et al. . Associations with and prognostic and discriminatory role of N-terminal pro-B-type natriuretic peptide in heart failure with preserved vs. mid-range vs. reduced ejection fraction. J Card Fail. 2018;24:365–74.
    1. Savarese G, Hage C, Orsini N, Dahlström U, Perrone-Filardi P, Rosano GM, et al. . Reductions in N-terminal pro-brain natriuretic peptide levels are associated with lower mortality and heart failure hospitalization rates in patients with heart failure with mid-range and preserved ejection fraction. Circ Heart Fail. 2016;9 pii: e003105.
    1. Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. . Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369:1587–97.
    1. James S, Rao SV, Granger CB. Registry-based randomized clinical trials–a new clinical trial paradigm. Nat Rev Cardiol. 2015;12:312–16.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren